A 12-month-old boy is evaluated in the primary care clinic for a routine health maintenance examination. His mother reports he has been doing well since a hospital admission 10 weeks ago. During that hospitalization, he was treated for 6 days of high fever, bilateral nonexudative conjunctivitis, mucosal changes, and cervical lymphadenopathy. His treatment included an infusion of intravenous immunoglobulin (IVIG) and high-dose oral aspirin. His immunizations were fully up to date prior to the illness. Growth parameters are normal. Physical examination today shows a healthy, active child with no significant findings. Which of the following is the most appropriate immunization strategy for this patient today?
- Administer inactivated vaccines today and defer live-attenuated vaccinesAnswer
- BAdminister all routine live-attenuated and inactivated vaccines today
- CDefer all vaccines for at least 11 months from his hospital discharge
- DCheck vaccine-specific antibody titers before administering any scheduled vaccines
- EAdminister live-attenuated vaccines today and defer inactivated vaccines
Answer
The most appropriate strategy is to administer the scheduled inactivated vaccines today while deferring the live-attenuated vaccines.
The patient recently received high-dose intravenous immunoglobulin (IVIG) for Kawasaki disease. IVIG contains a massive pool of passively acquired IgG antibodies. When a live-attenuated vaccine (such as the measles, mumps, rubella [MMR] or varicella vaccine typically given at 12 months) is administered to a patient with circulating IVIG, the passive antibodies neutralize the vaccine viruses, thereby preventing the viral replication necessary to stimulate an adequate active immune response. Consequently, live-attenuated vaccines must be postponed (up to 11 months following the high-dose IVIG used in Kawasaki disease). In contrast, the immunogenicity of inactivated vaccines (e.g., pneumococcal conjugate, Haemophilus influenzae type b, hepatitis A) is not significantly diminished by circulating antibodies. Therefore, the most appropriate strategy is to administer all due inactivated vaccines today to maintain timely protection against these pathogens, while deliberately deferring the live-attenuated vaccines until the passive antibodies have sufficiently degraded.
Step-by-Step Solution
Key Concept
Inactivated vaccines can be given simultaneously with or at any time after the administration of antibody-containing products (like IVIG). Live-attenuated vaccines must be deferred because passive antibodies can neutralize the vaccine virus and prevent an adequate immune response.